Pfizer Reports Favorable Results on Oral Tofacitinib for Ulcerative Colitis

Pfizer Reports Favorable Results on Oral Tofacitinib for Ulcerative Colitis
Pfizer recently released the top-line results from two Phase III induction studies of twice-daily tofacitinib (10 mg tablets) for ulcerative colitis, within the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) global program. According to the report, both clinical trials were successful at meeting specified primary endpoints, as determined by the number of patients treated with the drug

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *